MenQuadfi (MenACWY-TT): A New Vaccine for Meningococcal Serogroups ACWY. Issue 6 (June 2022)

• Record Type: Journal Article
• Authors: Huston, Jessica; Galicia, Kevin; Egelund, Eric F.
• Is Part Of: Annals of pharmacotherapy. Volume 56:Issue 6(2022)
• Page Start: 727
• Page End: 735
• Publication Date: 2022-06
• Subjects: meningococcal -- MenQuadfi -- vaccine -- MenACWY-TT; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; 615.5805
• DOI: 10.1177/10600280211039873
• Languages: English
• ISSNs: 1060-0280

Abstract

Objective: This article reviews data encompassing the pharmacology, efficacy, and safety of MenACWY-TT (MenQuadfi), a conjugate vaccine to prevent meningococcal disease from serogroups A, C, W, Y. Data Sources: A literature review was conducted in PubMed, MEDLINE, and ClinicalTrials.gov from inception up to July 2021, using the search terms MenQuadfi, meningococcal ACWY vaccine, MCV4, and menacwy . Articles from reference lists were included to identify potential relevant literature. Study Selection and Data Extraction: Data were limited to randomized phase II and III clinical studies published in the English language, evaluating the efficacy and safety of MenACWY-TT. Animal studies and studies not utilizing MenACWY-TT were excluded. Data Synthesis: One phase II and 4 phase III randomized clinical studies, enrolling approximately 7700 participants, aged 2 years to 97 years old found that MenACWY-TT was noninferior when compared to established MenACWY vaccines, as measured by surrogate immunogenicity end points. In studies evaluating primary dose vaccination, conducted in those aged 2 to 97 years of age, the difference in seroresponse rates, reported by the lower bound of the 95% CI, was (A) 1.1% to 14.8%, (C) 21% to 42.2%, (Y) 7.7% to 24.6%, and (W) 8.9% to 22.5%. Relevance to Patient Care and Clinical Practice: Despite the low incidence of meningococcal disease in the United States, meningococcal disease causes significant morbidity and mortality if not prevented. Conclusion: MenACWY-TT is noninferior to currently approved quadrivalent meningococcal vaccines and shows similar immunogenicity and safety as both an initial vaccine for prevention as well as a booster dose.